Successful Reversal of Furosemide-Induced Secondary Hyperparathyroidism With Cinacalcet.

Tarak Srivastava  
*Children's Mercy Hospital*

Shahryar Jafri  

William E. Truog  
*Children's Mercy Hospital*

Judith Sebestyen VanSickle  
*Children's Mercy Hospital*

Winston M. Manimtim  
*Children's Mercy Hospital*

*See next page for additional authors*

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/papers

Part of the Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Nephrology Commons, Pediatrics Commons, Pharmaceutical Preparations Commons, and the Respiratory Tract Diseases Commons

**Recommended Citation**

https://scholarlyexchange.childrensmercy.org/papers/1226

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact library@cmh.edu.
Successful Reversal of Furosemide-Induced Secondary Hyperparathyroidism With Cinacalcet

Tarak Srivastava, MD.a Shahryar Jafri, MD, William E. Truog, MD, Judith Sebestyen VanSickle, MD, Winston M. Manimtim, MD, Uri S. Alon, MD

Secondary hyperparathyroidism (SHPT) is a rare complication of furosemide therapy that can occur in patients treated with the loop diuretic for a long period of time. We report a 6-month-old 28-weeks premature infant treated chronically with furosemide for his bronchopulmonary dysplasia, who developed hypocalcemia and severe SHPT, adversely affecting his bones. Discontinuation of the loop diuretic and the addition of supplemental calcium and calcitriol only partially reversed the SHPT, bringing serum parathyroid hormone level down from 553 to 238 pg/mL. After introduction of the calcimimetic Cinacalcet, we observed a sustained normalization of parathyroid hormone concentration at 27 to 63 pg/mL and, with that correction, of all biochemical abnormalities and healing of the bone disease. No adverse effects were noted. We conclude that in cases of SHPT due to furosemide in which traditional treatment fails, there may be room to consider the addition of a calcimimetic agent.

Furosemide therapy in the neonatal/infantile period is well known to be associated with medullary nephrocalcinosis from hypercalciuria caused by the loop diuretic.1,2 A less known complication of chronic treatment with furosemide is the development of secondary hyperparathyroidism (SHPT).3–6 The latter is attributed to the hypercalciuria, leading to the development of hypocalcemia, which stimulates parathyroid hormone (PTH) secretion.6,7 But recent literature also suggests an additional, direct stimulating effect of furosemide on the parathyroid glands.8 It is expected that discontinuation of the loop diuretic, at times combined with supplementation with calcium and active vitamin D metabolites, will reverse the SHPT. However, if the parathyroid glands achieve a significant level of hyperplasia, the task of controlling SHPT will be difficult, and the endocrinopathy may persist for a prolonged period.

In recent years, a calcimimetic agent, Cinacalcet, which acts on the calcium-sensing receptor has become available to suppress PTH.9 The calcimimetic agent changes the configuration of the calcium-sensing receptor in the parathyroid glands, making them more sensitive to circulating serum calcium, resulting in decreased secretion of PTH. Although originally created for use in adults with SHPT, there have been now several reports of successful use of this agent in children with SHPT from various genetic and acquired etiologies.10–13 We report our novel experience in a premature infant with severe bronchopulmonary dysplasia (BPD) necessitating long-term treatment with furosemide who developed SHPT. After observing only partial response to traditional therapy with calcium and calcitriol, the SHPT...
was successfully reversed with Cinacalcet.

**CASE REPORT**

The child was born at 28 weeks’ gestation with a birth weight of 830 g. He was transferred from his birth hospital at 2 months of age for ongoing needs of prematurity, severe BPD, and possible need for tracheostomy. On admission to our institution, furosemide was added to his ongoing thiazide therapy to treat his respiratory condition. At age 5.5 months, he underwent tracheostomy and placement of ventriculoperitoneal shunt for hydrocephalus. MRI of the brain performed for evaluation of the ventriculoperitoneal shunt showed severe demineralization of the bones (Fig 1). The skeletal survey conducted the next day showed abnormal bony demineralization concerning for a metabolic bone disorder. That day serum ionized calcium (iCa) was 0.99 mmol/L (normal 1.13–1.37), and he was started on calcium supplementation. Further detailed evaluation in the coming days (Table 1, week –7.0), when his chronological age was 6 months and weight 6.3 kg, detected decreased serum calcium (8.9 mg/dL; iCa 1.09 mmol/L; elevated PTH (553 pg/mL), alkaline phosphatase (ALP; 420 U/L), and 1,25(OH)2 vitamin D (689 pg/mL); and normal phosphorus (5.4 mg/dL), 25(OH)-vitamin D (65 ng/mL), and urine calcium/creatinine ratio (0.22 mg/mg). At that time, his treatment of BPD included furosemide (3 mg/kg/day), chlorothiazide (22.5 mg/kg/day), and prednisone (0.5 mg/kg every 48 hours). Renal ultrasound showed no medullary nephrocalcinosis. His nutritional formula provided elemental calcium, phosphorus, and vitamin D of 603 mg/day, 437 mg/day, and 260 U/day, respectively. Genetic mutation analysis for conditions associated with inherited forms of rickets and/or osteopetrosis (namely VDR, CASR, PHEX, CYP27B1, CYP2R1, DMP1, CLCN7, SOST, LRPS4, SNX10, TMFSF11, TNFRSF11A, and OSTM1) were negative. A microarray did not identify any deletion or duplication. Calcitriol was added to address his hypocalcemia. Over the next 3 weeks, his serum PTH decreased but remained elevated at 257 pg/mL. (Table 1, week –3.4). At this point, our team was consulted, and the diagnosis of furosemide-induced SHPT was made. Furosemide was discontinued and the chlorothiazide dose doubled. In coming weeks, a further decrease in PTH levels was noted, but the dose of calcitriol and calcium supplementation had to be decreased to avoid hypercalcemia. Nevertheless, despite sustained normalization of serum calcium over this 6-week period, his serum PTH remained elevated (Table 1, week 0). After discussion with the family, a decision was made to initiate oral Cinacalcet 3 mg/day (0.4 mg/kg/day) in 2 divided doses. Over the next 2 weeks (Table 1: Cinacalcet Course A), PTH normalized at 15 to 25 pg/mL. Due to hypocalcemia, calcium supplementation was increased. With serum PTH and calcium levels within their normal range, Cinacalcet was subsequently discontinued (Table 1, week 2.0). Within the next 2 weeks, the serum PTH rebounded to 151 to 234 pg/mL. This suggested significant hyperplasia of the parathyroid glands requiring sustained pharmacological suppression of PTH. An attempt to image the parathyroid glands by using neck ultrasound failed because of neck size and presence of tracheostomy. At this point, Cinacalcet was reinitiated (Table 1: Cinacalcet Course B) with concomitant calcitriol and calcium supplementation. Serum PTH eventually normalized and stayed within the normal range for the next 12 weeks. Calcitriol was discontinued first, calcium supplementation was tapered and discontinued next, and finally Cinacalcet was stopped (Table 1, weeks 11.5–16.5). The child was then able to maintain serum calcium and PTH levels in their normal ranges until discharge 8 weeks later. At follow-up a month later, serum calcium and PTH were normal at 10.2 mg/dL and 78 pg/mL, respectively. The child tolerated therapy with Cinacalcet without any adverse effects. Throughout this course, his serum creatinine and urine calcium/creatinine ratio remained normal. The renal ultrasound on last follow-up showed no nephrocalcinosis. Serum ALP, which was originally elevated, gradually normalized. Follow-up radiographs done at 1 year of age showed normal mineralization with resolution of metaphyseal cupping and fraying (Fig 1).

**DISCUSSION**

Furosemide is a potent loop diuretic with action in the loop of Henle that results in decreased sodium and water reabsorption; it is often used in infants with BPD. However, its action also results in decreased calcium reabsorption because calcium and sodium reabsorption are coupled at this site. The increased urinary calcium excretion may result in formation of medullary nephrocalcinosis or stones. In older patients, furosemide has also been reported to be associated with decreased bone mineral density, osteoporosis, and high risk for fractures. In addition, there have been reports about the association of the loop diuretic with development of SHPT. 3–8 Coe et al in 1973 demonstrated that adults treated with furosemide had elevated PTH similar to adults with persistent hypercalciuria. In 1985, Fujita et al showed that adults treated for a week with oral furosemide had elevated urine calcium (effect on loop of Henle) and cyclic adenosine
monophosphate excretion (effect of elevated PTH). More recently, cross-sectional analyses of large data sets from the United States, Brazil, and Australia have shown the loop diuretic to be associated with SHPT in adults with both normal and reduced renal function. Similarily, Venkataraman et al reported that SHPT induced by furosemide has been previously reported in 4 preterm infants who consequently developed hyperparathyroid bone disease, but no additional pediatric cases have since been reported. Although SHPT from furosemide has been reported in adults, it seems to be a rarity in the pediatric population.

The mechanism of furosemide-induced SHPT has been conventionally attributed to increased urinary calcium excretion, but that alone does not completely explain the development of SHPT from calciuria. Riss et al showed that although thiazides decrease urine calcium excretion in primary hyperparathyroidism, they do not affect serum PTH level. Similarly, our case had SHPT despite normal urine calcium excretion, which could be explained by adjunctive thiazide therapy or a calcium-depleted skeleton. Another possible mechanism for the development of SHPT is based on the new observation of a direct stimulatory effect of furosemide on the parathyroid cells acting via the NKCC1 receptor.

In the present case, the infant, with ventilator-dependent BPD, was treated with furosemide for 4 months, when the brain MRI performed by adjunctive thiazide therapy showed severe osteopenia (Fig 1). The biochemical evaluation that followed was consistent with furosemide-induced SHPT (Table 1). After calcitriol and calcium supplementation decreased PTH only partially, furosemide was discontinued. Over the next 3 weeks, serum PTH further decreased but remained elevated. It was realized that further suppression of PTH secretion may come at the cost of hypercalcemia. Cinacalcet was therefore added, and subsequently PTH was decreased to its normal range (Table 1: Cinacalcet Course A). After Cinacalcet was stopped, PTH levels immediately rebounded and were brought back to normal with the reintroduction of the calcimimetic. We believe that the hormonal rebound provides a proof of concept that the suppression of PTH was the result of treatment with Cinacalcet and not coincidental.

Coe et al reported that SHPT associated with persistent hypercalciuria was secondary to hyperplasia of the glands and would respond to calcium infusion. Venkataraman et al reported that autopsy in one of the premature infants who developed furosemide-induced SHPT showed enlarged parathyroid glands. Our attempt to image the parathyroid glands was not successful due to presence of tracheostomy. However, on the basis of the course of events, we believe that also in our case, the parathyroid glands achieved a significant level of hyperplasia making the task of controlling SHPT more difficult; specifically, if left to conventional treatment, the state of SHPT would have persisted for a prolonged period. Cinacalcet, a calcimimetic that acts on the calcium-sensing receptor to suppress PTH secretion, was previously shown to be effective and safe in reversing various types of primary and SHPT in both adults and children. Furthermore, as recently shown by Muller et al, it negates the direct effect of furosemide on the parathyroid glands. It thus seems to be the ideal drug to use in a circumstance such as in our patient for rapid and safe correction of SHPT. As with our previous experience with vitamin D–resistant rickets and pseudohypoparathyroidism type 1b, and as was the case in our current patient, bringing serum PTH back into the normal range resulted in normalization of serum ALP and healing of the bone disease.
and humans, Cinacalcet’s main adverse effect was the development of hypocalcemia, requiring the adjustment of supplemental active vitamin D metabolite to sustain serum iCa concentration within its normal range.\textsuperscript{10,11,23}

Several lessons can be learned from the present case. In children chronically treated with a loop diuretic, close attention should be paid to their mineral metabolism, specifically periodic assessment of serum iCa and PTH levels and urine calcium should be performed. Once abnormalities are detected, all efforts should be made to discontinue the loop diuretic, and if diuresis is still required, the use of a thiazide diuretic is preferable. In case this maneuver does not help reverse SHPT, calcium and active vitamin D metabolites need to be added. If satisfactory suppression of PTH is still not noted, we now have in our armamentarium the calcimimetic agent. We recommend, on the basis of others’ and our own experience, continuing to monitor serum iCa and urine calcium closely because some patients under calcimimetic treatment develop hypocalcemia responding to calcitriol and/or hypercalciuria responding to thiazides.

**ACKNOWLEDGMENTS**

The off-label use of Cinacalcet in furosemide-induced SHPT was extensively discussed with the family. The family gave their consent for publication of the case report.

**ABBREVIATIONS**

ALP: alkaline phosphatase  
BPD: bronchopulmonary dysplasia  
iCa: ionized calcium  
PTH: parathyroid hormone  
SHPT: secondary hyperparathyroidism

### Table 1 Effect of Therapy With Elemental Calcium, Calcitriol, and Cinacalcet Before and On and Off Cinacalcet on Serum Biochemical Variables in a Premature Infant With Furosemide-Induced SHPT

<table>
<thead>
<tr>
<th>Time, wk</th>
<th>Elemental Calcium, mg/d</th>
<th>Calcitriol, µg/d</th>
<th>Cinacalcet, mg/d</th>
<th>iCa, mmol/L</th>
<th>Serum P, mg/dL</th>
<th>Serum PTH, pg/mL</th>
<th>Serum ALP, U/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference range</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>1.13–1.37</td>
<td>4.2–7.0</td>
<td>10–89</td>
</tr>
<tr>
<td>Pre-cinacalcet</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>5.4</td>
<td>—</td>
<td>1.09</td>
</tr>
<tr>
<td>—7.0</td>
<td>560</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>5.4</td>
<td>553</td>
<td>420</td>
</tr>
<tr>
<td>—6.1</td>
<td>560</td>
<td>0.15</td>
<td>—</td>
<td>—</td>
<td>4.9</td>
<td>531</td>
<td>419</td>
</tr>
<tr>
<td>—5.0</td>
<td>560</td>
<td>0.30</td>
<td>—</td>
<td>—</td>
<td>5.4</td>
<td>484</td>
<td>553</td>
</tr>
<tr>
<td>—3.4\textsuperscript{a}</td>
<td>560</td>
<td>0.30</td>
<td>—</td>
<td>—</td>
<td>6.6</td>
<td>257</td>
<td>—</td>
</tr>
<tr>
<td>—2.6</td>
<td>560</td>
<td>0.30</td>
<td>—</td>
<td>—</td>
<td>6.3</td>
<td>161</td>
<td>—</td>
</tr>
<tr>
<td>—1.4\textsuperscript{b}</td>
<td>280</td>
<td>0.15</td>
<td>—</td>
<td>—</td>
<td>5.9</td>
<td>157</td>
<td>336</td>
</tr>
<tr>
<td>0.0</td>
<td>280</td>
<td>0.15</td>
<td>—</td>
<td>—</td>
<td>5.6</td>
<td>238</td>
<td>335</td>
</tr>
<tr>
<td>Cinacalcet course A</td>
<td>0.8</td>
<td>280</td>
<td>0.15</td>
<td>6.9</td>
<td>1.17</td>
<td>5.4</td>
<td>137</td>
</tr>
<tr>
<td>1.0</td>
<td>280</td>
<td>0.15</td>
<td>7.8</td>
<td>1.33</td>
<td>5.7</td>
<td>25</td>
<td>—</td>
</tr>
<tr>
<td>1.6</td>
<td>280</td>
<td>0.15</td>
<td>6.0</td>
<td>1.01</td>
<td>6.0</td>
<td>15</td>
<td>—</td>
</tr>
<tr>
<td>2.0\textsuperscript{c}</td>
<td>600</td>
<td>0.15</td>
<td>6.0</td>
<td>1.12</td>
<td>6.0</td>
<td>25</td>
<td>—</td>
</tr>
<tr>
<td>Off cinacalcet</td>
<td>2.6</td>
<td>600</td>
<td>0.15</td>
<td>—</td>
<td>1.27</td>
<td>6.2</td>
<td>234</td>
</tr>
<tr>
<td>3.6</td>
<td>600</td>
<td>0.15</td>
<td>—</td>
<td>—</td>
<td>1.31</td>
<td>5.9</td>
<td>151</td>
</tr>
<tr>
<td>Cinacalcet course B</td>
<td>4.5</td>
<td>600</td>
<td>0.15</td>
<td>3.5</td>
<td>1.26</td>
<td>5.1</td>
<td>117</td>
</tr>
<tr>
<td>6.8\textsuperscript{d}</td>
<td>780</td>
<td>0.15</td>
<td>7.2</td>
<td>1.21</td>
<td>7.6</td>
<td>119</td>
<td>—</td>
</tr>
<tr>
<td>8.0</td>
<td>780</td>
<td>0.15</td>
<td>6.9</td>
<td>1.19</td>
<td>7.1</td>
<td>10</td>
<td>—</td>
</tr>
<tr>
<td>9.0</td>
<td>780</td>
<td>0.15</td>
<td>6.6</td>
<td>1.17</td>
<td>7.6</td>
<td>90</td>
<td>—</td>
</tr>
<tr>
<td>10.5</td>
<td>780</td>
<td>0.15</td>
<td>3.3</td>
<td>1.31</td>
<td>5.9</td>
<td>63</td>
<td>—</td>
</tr>
<tr>
<td>11.5</td>
<td>780</td>
<td>0.15</td>
<td>3.3</td>
<td>1.34</td>
<td>8.7</td>
<td>92</td>
<td>—</td>
</tr>
<tr>
<td>12.5</td>
<td>780</td>
<td>—</td>
<td>5.4</td>
<td>1.29</td>
<td>5.7</td>
<td>104</td>
<td>—</td>
</tr>
<tr>
<td>13.5</td>
<td>780</td>
<td>—</td>
<td>4.8</td>
<td>1.19</td>
<td>8.2</td>
<td>27</td>
<td>—</td>
</tr>
<tr>
<td>14.5</td>
<td>780</td>
<td>—</td>
<td>4.8</td>
<td>1.23</td>
<td>7.2</td>
<td>44</td>
<td>—</td>
</tr>
<tr>
<td>15.5</td>
<td>780</td>
<td>—</td>
<td>4.8</td>
<td>1.27</td>
<td>6.9</td>
<td>28</td>
<td>—</td>
</tr>
<tr>
<td>16.5</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>2.4</td>
<td>1.28</td>
<td>7.6</td>
<td>55</td>
</tr>
<tr>
<td>Off cinacalcet</td>
<td>18.0</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>1.38</td>
<td>7.3</td>
<td>63</td>
</tr>
<tr>
<td>20.5</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>1.32</td>
<td>5.8</td>
<td>35</td>
<td>—</td>
</tr>
<tr>
<td>24.5</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>1.37</td>
<td>5.9</td>
<td>45</td>
<td>—</td>
</tr>
</tbody>
</table>

Serum creatinine ranged between 0.22 and 0.29 mg/dL throughout the study period (reference range 0.06–0.45 mg/dL).

\textsuperscript{a} Furosemide was discontinued and dose of chlorothiazide doubled.

\textsuperscript{b} Calcium and calcitriol supplementation were decreased due to hypercalcemia (iCa 1.43 at week –2.6).

\textsuperscript{c} Calcium supplementation was increased due to hypocalcemia (iCa 1.01 at week 1.6).

\textsuperscript{d} Calcium supplementation was increased due to hypocalcemia (iCa 1.06 at week 6).

Table adapted with permission from Srivastava et al.\textsuperscript{4}


Successful Reversal of Furosemide-Induced Secondary Hyperparathyroidism With Cinacalcet


*Pediatrics* 2017;140;
DOI: 10.1542/peds.2016-3789 originally published online November 30, 2017;

Updated Information & Services
including high resolution figures, can be found at:
http://pediatrics.aappublications.org/content/140/6/e20163789

References
This article cites 23 articles, 1 of which you can access for free at:
http://pediatrics.aappublications.org/content/140/6/e20163789#BIBL

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Nephrology
http://www.aappublications.org/cgi/collection/nephrology_sub

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.aappublications.org/site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online:
http://www.aappublications.org/site/misc/reprints.xhtml
Successful Reversal of Furosemide-Induced Secondary Hyperparathyroidism With Cinacalcet

Pediatrics 2017;140;
DOI: 10.1542/peds.2016-3789 originally published online November 30, 2017;

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/140/6/e20163789